Posted on 1/10/18
Johnson & Johnson Wants to Create a Crisis -- and That's Great for Investors
Johnson & Johnson (NYSE:JNJ) CEO Alex Gorsky, along with CFO Dominic Caruso, sat down on Monday to answer questions at the annual J.P. Morgan Healthcare Conference. . . .
Posted on 1/10/18
3 Dividend Stocks That Cut Bigger Checks Than Johnson & Johnson
Healthcare giant Johnson & Johnson (NYSE:JNJ) pays a nice dividend. Based on its latest quarterly payout, the stock yields about 2.3%. That may not seem all . . .
Posted on 1/9/18
WellCare of New York Rated Among High Performing Medicaid Health Plans in the State
With high performance scores in several key preventative and treatment categories, WellCare of New York, Inc., a subsidiary of WellCare Health Plans, Inc. (NYSE: WCG), earned . . .
Posted on 1/9/18
Pfizer (PFE) Presents at JPMorgan Healthcare Conference - Transcript
Pfizer Inc. (NYSE:PFE) JPMorgan Healthcare Conference January 8, 2018 11:30 AM ETExecutivesMikael Dolsten - President, Worldwide Research and DevelopmentAnalystsChris Schott - J.P. MorganChris SchottGood morning, everybody. . . .
Posted on 1/9/18
Johnson & Johnson: A Good Value In This Overheated Market
Johnson & Johnson is a blue chip dividend aristocratWhen I think of Johnson & Johnson (JNJ), I can’t help but think of high quality. Many refer . . .
Posted on 1/8/18
3 Big Biotech Stocks to Buy in January
Biotech was hot yet again in 2017. The SPDR S&P Biotech ETF soared more than 43% last year. Many biotech stocks performed even better than that.For . . .
Posted on 1/8/18
iBio Provides Corporate Update
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) --IBIO, INC.(NYSE AMERICAN:IBIO) announced today its receipt of notice that Staff of NYSE American LLC determined that the Company’s . . .
Posted on 1/8/18
CDPHP Named among the Best Companies to Work for in NY
Albany, NY, Jan. 05, 2018 (GLOBE NEWSWIRE) -- CDPHP has once again been named one of the Best Companies to Work for in New York, making . . .
Posted on 1/8/18
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that onJanuary 3, 2018 it approved non-statutory stock options to purchase an aggregate of 33,200 shares of its common . . .
Posted on 1/4/18
Bristol-Myers Squibb Leads $75M Series B For Personal Genome Diagnostics
Personal Genome Diagnostics Inc. (PGDx) today announced a $75 million Series B financing co-led by new investor Bristol-Myers Squibb and existing investor
Posted on 1/4/18
Johnson & Johnson Presents A Good Investment Case With Tremfya
Johnson & Johnson (JNJ) had a strong 2017 both on and off the stock market. The company stock maintained an upward trend throughout the year. Johnson . . .
Posted on 1/4/18
3 Biotech Stocks to Buy in January
Biotechnology stocks performed exceptionally well last year, and this positive trend appears set to continue in 2018. As such, investors may want to kick off the . . .
Posted on 1/3/18
Biostage Closes $4.2 Million Private Placement
Biostage, Inc. (OTCQB: BSTG/BSTGD), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced . . .
Posted on 1/3/18
Altus Capital Partners Completes Tender Offer for MGC Diagnostics
WILTON, Conn.--(BUSINESS WIRE)--Altus Capital Partners, Inc., an investment firm focused on the North American manufacturing sector, announced the successful conclusion of the tender offer for all . . .
Posted on 1/3/18
CytoSorbents To Provide Corporate Update at Biotech Showcase 2018
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around . . .
Posted on 1/3/18
Celgene - Don't Forget The Pipeline
A tale of two halves - 20172017 has been an interesting year for Celgene as a whole. What began in 2017 as a strong bull-run for . . .
Posted on 1/3/18
3 Best Big Pharma Stocks to Buy for 2018
If you're expecting massive revenue growth for 2018 among big pharma stocks, think again. Despite hot new drugs for several major drugmakers, many of them also . . .
Posted on 1/3/18
Should You Buy Bristol-Myers Squibb Stock in 2018?
Bristol-Myers Squibb (NYSE:BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit . . .
Posted on 1/3/18
Better Buy: Procter & Gamble Company vs. Philip Morris International
Procter & Gamble (NYSE:PG) and Philip Morris (NYSE:PM) have long been bastions of bountiful dividend income for investors. With the consumer-goods giant and tobacco titan currently . . .
Posted on 1/2/18
Horizon Technology Finance Provides $12 Million Venture Loan to Conventus Orthopaedics
Horizon Technology Finance Corporation (NASDAQ: HRZN), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in . . .
Posted on 12/31/17
Delcath Announces Exit from Convertible Note
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, . . .
Posted on 12/30/17
Brainstorm Issues 2017 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to Shareholders from its President . . .
Posted on 12/22/17
Akers Biosciences Announces Closing of $6,900,000 Public Offering
THOROFARE, N.J., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), a developer of rapid health information technologies, today announces the closing . . .
Posted on 12/21/17
Aetna Joins SAFE-BioPharma Association
TENAFLY, N.J.--(BUSINESS WIRE)--SAFE-BioPharma Association today announced that Aetna, one of the nation’s leading diversified health care benefits companies, has become its most recent member. It is . . .
Posted on 12/21/17
Ionis Earns $5M Milestone From J&J On Initiation Of Early-Stage Study Of Orally Delivered Antisense Drug For GI Disorders
Ionis Pharmaceuticals (NASDAQ:IONS) initiates a Phase 1 clinical trial assessing its first orally delivered antisense drug, IONIS-JBI1-2.5rx, for the treatment of an unspecified gastrointestinal (GI) immune . . .

